Oncology Consultations®: Collaborative Management of Ocular Toxicities in Patients with Relapsed/Refractory Multiple Myeloma

Release Date: June 30, 2021
Expiration Date: June 30, 2022

Activity Overview

The antibody-drug conjugate (ADC) belantamab mafodotin (belamaf) is used to treat relapsed/refractory multiple myeloma (R/R MM) that is refractory to immunomodulatory drugs (IMiD), proteasome inhibitors (PIs), and anti-CD38 mAb therapy, otherwise known as triple-class refractory myeloma. However, belamaf is also associated with frequent ocular adverse events that can cause symptoms such as blurry vision. Its administration requires a multidisciplinary approach that includes oncologists and eye care specialists, to monitor patients for ocular toxicities and adjust drug dosage when necessary. In this educational activity, an expert ophthalmologist and an oncologist review strategies to monitor, grade, and manage ocular toxicities associated with ADCs, and review how to apply collaborative strategies between specialties to best monitor and educate patients.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Target Audience

This educational activity is intended for hematologists/oncologists, ophthalmologists, and optometrists.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the impact of disease-related factors, risk assessment, and treatment history on antibody-based therapy decisions in R/R MM
• Evaluate the clinical profiles of antibody-based therapies in R/R MM
• Implement strategies to monitor, grade, and manage ocular toxicities associated with ADCs
• Apply effective collaborative strategies for the multidisciplinary management of ADC-related ocular toxicities

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Sagar Lonial, MD, FACP
Professor and Chair
Department of Hematology and Medical Oncology
Anne and Bernard Gray Professor in Cancer
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, GA

Disclosures: Grant/Research Support: BMS, Celgene, Janssen, Takeda; Consultant: AbbVie, Amgen, BMS, Celgene, GSK, Janssen Sanofi, Novartis, Takeda; Other: TG Therapeutics (Board of Directors).

Shaily Dinesh Shah, MD
Associate Ophthalmologist
Northern California Cornea Associates, Inc.
Attending Ophthalmologist/Teaching Faculty
Department of Ophthalmology
Highland Hospital
Oakland, CA

Disclosures: Speaker’s Bureau: GlaxoSmithKline.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.